Inhibrx: Spinoff Rumors Send Shares Soaring - Stunning Bull Run Can Continue [Seeking Alpha]
Inhibrx Biosciences, Inc. (INBX)
Company Research
Source: Seeking Alpha
Ozekibart's Phase 2 data in chondrosarcoma showed a 52% risk reduction in progression or death, positioning INBX as a first-mover in an unmet oncology market. INBRX-106, in combination with Keytruda, is advancing through Phase 2/3 trials, with key data readouts and potential spinoff partnerships as near-term catalysts. Despite strong upside potential and a $300 price target from Stifel, INBX financing remains a risk, with upcoming BLA submissions and pivotal data as critical inflection points. Looking for more investing ideas like this one? Get them exclusively at Haggerston BioHealth. Learn More » Cinefootage Visuals/iStock via Getty Images Investment Overview The stock of La Jolla, California-based biotech company Inhibrx Biosciences, Inc. ( INBX ) is surging in value today, up nearly 40% for the day, as it is rumoured several high profile Pharma companies are keen More on my IG service If you are interested in keeping up to date with stocks making moves within the
Show less
Read more
Impact Snapshot
Event Time:
INBX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INBX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INBX alerts
High impacting Inhibrx Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
INBX
News
- Why Inhibrx Biosciences (INBX) Is Up 46.3% After New Ozekibart Colorectal Cancer Data And FDA Plans [Yahoo! Finance]Yahoo! Finance
- Inhibrx Biosciences Highlights 20% ORR for Ozekibart Combo in Late-Line Colorectal Cancer [Yahoo! Finance]Yahoo! Finance
- Inhibrx Biosciences (INBX) was upgraded by Lifesci Capital to "strong-buy".MarketBeat
- T-Mobile reportedly in merger talks, Adobe's $25B stock buyback [Yahoo! Finance Canada]Yahoo! Finance Canada
- Inhibrx cancer drug reportedly drawing interest of Merck and rivals [Seeking Alpha]Seeking Alpha
INBX
Earnings
- 8/13/25 - Beat
INBX
Sec Filings
- 4/27/26 - Form 4
- 4/23/26 - Form ARS
- 4/23/26 - Form DEF
- INBX's page on the SEC website